Skip to content
GLP-1 Savers

Research & guides

Does Medicaid Cover GLP-1s? State Rules and Coverage Exceptions

Medicaid GLP-1 coverage varies by state, diagnosis and age. California, North Carolina and Pennsylvania examples, plus the limits of BALANCE.

By Grant Ashford, Founder & Pricing Editor
What's in this guide

Medicaid may cover a GLP-1, but there is no single national yes-or-no answer for weight loss. Check the state program, prescribed drug and reason for treatment before paying cash. An obesity exclusion does not necessarily mean the same drug is excluded for every other indication.

The examples below were checked against state sources in October 2026. They are a limited policy snapshot, not a 50-state coverage list or an individual eligibility decision.

Three state policies that show why the details matter

StateWeight-loss coverage
CaliforniaNot covered for adults 21+ from January 2026; exceptions apply
North CarolinaRestored December 2025; prior authorization required
PennsylvaniaDiscontinued January 2026; other indications and under-21 exceptions remain

California: a weight-loss exclusion with exceptions

Medi-Cal Rx's member notice says prior approvals for weight-loss-only Wegovy, Zepbound and Saxenda ended December 31, 2025. It directs prescribers to request authorization for Zepbound used for obstructive sleep apnea and Wegovy for cardiovascular disease. Wegovy coverage for noncirrhotic MASH continues when the prescriber submits the diagnosis code. Diabetes-drug coverage remains subject to approval. Members younger than 21 may still receive medically necessary weight-loss treatment with an approved request under EPSDT, the federal children's benefit1. Do not read California's adult exclusion as a ban on every GLP-1 use.

North Carolina: the cancellation was reversed

An older notice saying North Carolina ended obesity-drug coverage in October 2025 is incomplete. The state reinstated it effective December 12, 2025 for Medicaid Direct and managed care. Its reinstatement bulletin lists Wegovy as preferred and Zepbound and Saxenda as nonpreferred: approval of the latter requires trying and failing Wegovy or documenting why it cannot be used2. The restoration still requires clinical review; it is not automatic access to any brand.

Pennsylvania: check age and indication

Pennsylvania's notice ended GLP-1 coverage for overweight and obesity beginning January 1, 2026. It preserves coverage for other medically accepted indications with prior authorization3. Jefferson Health Plans separately confirms that members under 21 may receive medical-necessity review under EPSDT6. Ask your plan which rule applies to your prescription instead of assuming an older approval will renew.

BALANCE is voluntary, not nationwide coverage

CMS's BALANCE model allows state Medicaid agencies to join between May 2026 and January 1, 2027. Coverage depends on state and manufacturer participation, clinical eligibility and prior authorization. CMS explicitly says the model does not guarantee coverage for an individual4.

Ask whether your state has actually started participating, which products it covers and when your own coverage could begin. A federal announcement or a state's application is not a paid pharmacy claim. The Medicare GLP-1 Bridge is a separate program; its advertised copay is not a nationwide Medicaid price.

How to get an answer for your prescription

  1. Ask the number on your Medicaid card who manages your pharmacy benefit.
  2. Give the exact drug, device and diagnosis. Request the current preferred drug list and authorization criteria.
  3. Have your prescriber check the documentation, age rules and any preferred-drug requirement.
  4. Ask the pharmacy for the covered charge after approval, including whether another pharmacy is required.
  5. If denied, request the written reason and your plan's appeal instructions before buying a recurring cash plan.

Keep the date, policy name and response. This is especially useful when a published policy changes before every managed-care system has caught up.

A manufacturer coupon is not a substitute for Medicaid coverage

Lilly's commercial Zepbound savings card excludes Medicaid beneficiaries5. Having Medicaid that denies a particular prescription does not turn you into a commercially insured cardholder. Our savings-card guide separates that offer from self-pay options.

If you must compare cash prices, first ask your plan and pharmacy which payment arrangements are permitted and whether any spending would count toward your benefits. Compare the full ongoing bill, not a first-fill advertisement. Zepbound insurance coverage explains the difference between plan approval, a coupon and a cash purchase.

Frequently asked questions

Does Medicaid cover GLP-1s for weight loss in every state?

No. The answer depends on the state, drug, age, indication and authorization rules. Coverage for diabetes or another indication does not establish coverage for weight loss.

Does BALANCE guarantee that Medicaid pays for Zepbound?

No. CMS says coverage depends on participating states and manufacturers, patient qualifications and prior authorization. Verify that your state has implemented coverage and that your prescription meets its rules.

Can I use a Zepbound commercial savings card if Medicaid denies it?

No. The commercial savings card excludes Medicaid beneficiaries even when Medicaid does not cover that prescription.

References

  1. California Department of Health Care Services (2025). Changes to GLP-1 Drug Coverage – Effective January 1, 2026. Medi-Cal Rx. https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/member/GLP1_Changes.pdf
  2. NC Medicaid (2025). NC Medicaid to Reinstitute Coverage of GLP-1s for Weight Management. NC Medicaid. https://medicaid.ncdhhs.gov/blog/2025/12/19/nc-medicaid-reinstitute-coverage-glp-1s-weight-management
  3. Pennsylvania Department of Human Services (2025). Medical Assistance Program Compensable Service Change: GLP-1 Drugs to Treat Overweight and Obesity. Pennsylvania Bulletin. https://www.pacodeandbulletin.gov/secure/pabulletin/data/vol55/55-52/1777.html
  4. Centers for Medicare & Medicaid Services (2026). BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model. CMS.gov. https://www.cms.gov/priorities/innovation/innovation-models/balance
  5. Eli Lilly and Company (2026). Savings & Insurance Options | Zepbound® (tirzepatide). zepbound.lilly.com. https://zepbound.lilly.com/savings
  6. Jefferson Health Plans (2026). GLP-1. Jefferson Health Plans. https://www.jeffersonhealthplans.com/medicaid/get-care/find-a-covered-drug/glp-1/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.